None listed
Conditions
Interventions
Group 1 Type of group
Alogliptin 12.5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.
Group name:Group 3 Type of group
Glipizide 5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks. After at least 2 weeks of treatment but prior to Week 20, participants with persistent hyperglycemia (fasting plasma glucose ≥
250 mg/dL) underwent a dose titration of glipizide up to 20 mg in 5-mg increments in 4-week intervals.
Sponsors
TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER, INC.,
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: • Has a diagnosis of type 2 diabetes mellitus. • Must meet one of the following: • Has been inadequately controlled on a stable daily dose of =1500 mg (or documented maximum tolerated dose) of metformin for at least 2 months prior to Screening. • Has been inadequately controlled (as defined by a glycosylated hemoglobin 7.5 - 10%, inclusive) on metformin <1500 mg without documented maximum tolerated dose. - No treatment with antidiabetic agents other than metformin within 2 months prior to Screening (for Schedule A)/Pre-Screening (for Schedule B). • Has body mass index within 23 kg/m^2 and 45 kg/m^2 unless the patient is Asian or of Asian descent, for whom the allowable body mass index will be = 20 kg/m^2 and = 35 kg/m^2, inclusive. • Has fasting C-peptide concentration at least 0.8 ng. • If regularly using non-excluded medications, must be on a stable dose at least 4 weeks prior to Screening/Pre-screening. • Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant, lactating or intends to donate ova from Screening throughout the duration of the study. • Must be able and willing to monitor their blood glucose concentrations with a home monitor, and comply with protocol requirements including scheduled clinic appointments.
Exclusion criteria
Exclusion criteria: • Systolic blood pressure greater than or equal to 150 mmHg and/or diastolic pressure greater than or equal to 90. • Hemoglobin less than or equal to 12 g/dL for males and less than or equal to 10 g/dL for females at Screening Visit. • Alanine aminotransferase greater than or equal to 2.5 times the upper limit of normal at Screening Visit. • Serum creatinine greater than or equal to 1.5 mg/dL for males and 1.4 for females, or calculated creatinine clearance less than 60 L/min. • Males intending to impregnate others or donate sperm before, during or within 1 month after participating in the study. • A history of cancer other than squamous or basal cell carcinoma of the skin that has not been in full remission for at least 5 years. • A history of laser treatment for diabetic retinopathy within 6 months of screening. • Treated for diabetic gastric paresis, gastric banding, or gastric bypass. • New York Heart Association Class III or IV heart failure. • History of coronary angioplasty, coronary stent placement, coronary bypass surgery, myocardial infarction, stroke or transient ischemic attack within 3 months prior to screening. • Known history of human immunodeficiency virus, hepatitis B or C. • Alcohol or substance abuse within 2 years prior to screening. • Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including: • Any investigational drug within 30 days • Any investigational diabetic drug within 3 months • Any antidiabetic drug in the dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 mimetics classes within 90 days prior to Screening other than metformin • Prior treatment with alogliptin. • Weight-loss drugs • Oral or systemically injected glucocorticoids • A hypersensitivity allergy or anaphylactic reaction to any dipeptidyl peptidase-4 drug, metformin or glipizide. • Has a documented history or concurrent signs of significant thyroid disease (eg, autoimmune thyroid diseases such as Graves disease and Hashimoto thyroiditis or active thyroid nodules).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcome name:The change from Baseline to Week 52 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). The least squares (LS) means are from an analysis of covariance (ANCOVA) model with treatment, study schedule, and geographic region as class variables, and Baseline metformin dose and Baseline HbA1c as covariates. Measure:Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 52 Timepoints:Week 52 ; Outcome name:The change from Baseline to Week 104 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). The least squares (LS) means are from an analysis of covariance (ANCOVA) model with treatment, study schedule, and geographic region as class variables, and Baseline metformin dose and Baseline HbA1c as covariates. Measure:Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 104 Timepoints:Week 104 | — |
Secondary
| Measure | Time frame |
|---|---|
| Outcome name:The change from Baseline over time in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). LS means are from an ANCOVA model with treatment, study schedule, and geographic region as class variables, and Baseline metformin dose and Baseline HbA1c as covariates. Measure:Change From Baseline in Glycosylated Hemoglobin at Other Time Points Timepoints:Baseline and Weeks 4, 8, 12, 16, 20, 26, 39, 65, 78, and 91. ; Outcome name:The change from Baseline in fasting plasma glucose (FPG) was assessed at Weeks 2, 4, 8, 12, 16, 20, 26, 39, 52, 65, 78, 91, and 104. LS means are from an ANCOVA model with treatment, study schedule, and geographic region as class variables, and Baseline FPG and Baseline metformin dose as covariates. Measure:Change From Baseline in Fasting Plasma Glucose Over Time Timepoints:Baseline and Weeks 2, 4, 8, 12, 16, 20, 26, 39, 52, 65, 78, 91, and 104 ; Outcome name:The percentage of participants with HbA1c less than or equal to 6.5% at Weeks 26, 52, 78, and 104. Participants who did not complete the scheduled Week 104 visit were assessed based on their response at the time of discontinuation. Measure:Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 6.5% Timepoints:Weeks 26, 52, 78, and 104 ; Outcome name:Percentage of participants with HbA1c ≤ 7.0% at Weeks 26, 52, 78, and 104. Participants who did not complete the scheduled Week 104 visit were assessed based on their response at the time of discontinuation. Measure:Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 7.0% Timepoints:Weeks 26, 52, 78, and 104. ; Outcome name:LS Means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and Baseline weight and Baseline metformin dose as covariates. Measure:Change From Baseline in Body Weight Over Time Timepoin | — |
Countries
Argentina, Australia, Austria, Brazil, Canada, Chile, Germany, Guatemala, Hong Kong, Hungaria, India, Israel, Italy, Korea South, Latovia, Lithuania, Malasya, Mexico, New Zealand, Philippines, Poland, Romania, Russian Federation, Singapore, South Africa, Spain, Thailand, Ukraine, United Kindgdom, United States
Outcome results
None listed